Cargando…

Methylation pattern of caveolin-1 in prostate cancer as potential cfDNA biomarker

High prevalence and mortality of prostate cancer (PCa) are well-known global health issues. Novel biomarkers for better identifying patients with PCa are the subject of extensive research. Prostate-specific antigen (PSA) shows low specificity in screening and diagnostics, leading to unnecessary biop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Škara, Lucija, Vodopić, Tonći, Pezelj, Ivan, Abramović, Irena, Vrhovec, Borna, Vrtarić, Alen, Sinčić, Nino, Tomas, Davor, Bulimbašić, Stela, Kuliš, Tomislav, Ulamec, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901895/ https://www.ncbi.nlm.nih.gov/pubmed/36036057 http://dx.doi.org/10.17305/bjbms.2022.7497

Ejemplares similares

The utility of cfDNA in TGCT patient management: a systematic review
por: Krasic, Jure, et al.
Publicado: (2022)

MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia
por: Abramovic, Irena, et al.
Publicado: (2021)

Prostate Cancer—Focus on Cholesterol
por: Škara, Lucija, et al.
Publicado: (2021)

CNV Hotspots in Testicular Seminoma Tissue and Seminal Plasma
por: Raos, Dora, et al.
Publicado: (2021)

Testicular Germ Cell Tumor Tissue Biomarker Analysis: A Comparison of Human Protein Atlas and Individual Testicular Germ Cell Tumor Component Immunohistochemistry
por: Krasic, Jure, et al.
Publicado: (2023)

Impact of Preanalytical and Analytical Methods on Cell-Free DNA Diagnostics
por: Krasic, Jure, et al.
Publicado: (2021)

Teratoma Growth Retardation by HDACi Treatment of the Tumor Embryonal Source
por: Krasic, Jure, et al.
Publicado: (2020)

In Search of TGCT Biomarkers: A Comprehensive In Silico and Histopathological Analysis
por: Raos, Dora, et al.
Publicado: (2020)

Microfluidic Technologies for cfDNA Isolation and Analysis
por: Xu, Zheyun, et al.
Publicado: (2019)

Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022)

cfDNA Sequencing: Technological Approaches and Bioinformatic Issues
por: Bohers, Elodie, et al.
Publicado: (2021)

Plasma cfDNA predictors of established bacteraemic infection
por: Urosevic, Nadezda, et al.
Publicado: (2022)

Plasma cfDNA for the Diagnosis and Prognosis of Colorectal Cancer
por: Wu, Zhiwei, et al.
Publicado: (2022)

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
por: Fairclough, Stephen R., et al.
Publicado: (2019)

In silico error correction improves cfDNA mutation calling
por: Kim, Chang Sik, et al.
Publicado: (2019)

Comparison of the source and prognostic utility of cfDNA in trauma and sepsis
por: Jackson Chornenki, Nicholas L., et al.
Publicado: (2019)

Novel technologies in cfDNA analysis and potential utility in clinic
por: Li, Jie, et al.
Publicado: (2021)

cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome
por: Gerard, Laura, et al.
Publicado: (2021)

Epigenetically inactivated RASSF1A as a tumor biomarker
por: Raos, Dora, et al.
Publicado: (2021)

Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA
por: Togneri, Fiona S, et al.
Publicado: (2016)

cfDNA screening and diagnosis of monogenic disorders – where are we heading?
por: Chiu, Eunice Ka Long, et al.
Publicado: (2018)

Detection of LINE-1 hypomethylation in cfDNA of Esophageal Adenocarcinoma Patients
por: Boldrin, Elisa, et al.
Publicado: (2020)

Impact of mosaicism ratio on positive predictive value of cfDNA screening
por: Rafalko, Jill M., et al.
Publicado: (2020)

cfDNA Changes in Maximal Exercises as a Sport Adaptation Predictor
por: Humińska-Lisowska, Kinga, et al.
Publicado: (2021)

Deep cfDNA fragment end profiling enables cancer detection
por: Zhitnyuk, Yulia V., et al.
Publicado: (2022)

Dynamics of Specific cfDNA Fragments in the Plasma of Full Marathon Participants
por: Sugasawa, Takehito, et al.
Publicado: (2021)

Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer
por: Liang, Leilei, et al.
Publicado: (2022)

cfDNA Methylation Profiles and T-Cell Differentiation in Women with Endometrial Polyps
por: Li, Xiao-Hong, et al.
Publicado: (2022)

Hypertensive disorders of pregnancy share common cfDNA methylation profiles
por: Spinelli, Marialuigia, et al.
Publicado: (2022)

Brave new world of cfDNA-omics for early cancer detection
por: Rolfo, Christian, et al.
Publicado: (2023)

Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing
por: Medina Diaz, Inga, et al.
Publicado: (2016)

Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients
por: Vrabel, David, et al.
Publicado: (2019)

Beyond the Blood: CSF-Derived cfDNA for Diagnosis and Characterization of CNS Tumors
por: McEwen, Abbye E., et al.
Publicado: (2020)

Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer
por: Silva, Romina, et al.
Publicado: (2021)

MSIsensor-ct: microsatellite instability detection using cfDNA sequencing data
por: Han, Xinyin, et al.
Publicado: (2021)

Evaluation of cfDNA as an early detection assay for dense tissue breast cancer
por: Barbirou, Mouadh, et al.
Publicado: (2022)

Erratum to “The utility of cfDNA in TGCT patient management: a systematic review”
Publicado: (2022)

cfDNA methylome profiling for detection and subtyping of small cell lung cancers
por: Chemi, Francesca, et al.
Publicado: (2022)

The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma
por: Marivel, A-M Joëlle, et al.
Publicado: (2023)

The influence of hypoxic physical activity on cfDNA as a new marker of vascular inflammation
por: Pokrywka, Andrzej, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8i5np3ntgsgbdvd1kvejjml356